Loading MHRA search...
Drug Safety Update
Volume 6, Issue 9 April 2013
Latest advice for medicines users
Welcome to the latest issue of
Drug Safety Update
April 2013 (Volume 6, Issue 9)
Drug Safety Update is essential reading for all healthcare professionals, bringing you the very latest information and advice to support the safer use of medicines.
Drug safety advice
-
Insulin degludec (Tresiba▼): available in additional higher strength than existing insulins—care needed to minimise risk of error, including training for patients
Insulin degludec (Tresiba▼) is available in prefilled pen devices (known as FlexTouch) in two strengths: 100 units/mL; and 200 units/mL. The 100 units/mL strength is also available in cartridge form (called Penfill). -
Cilostazol (Pletal): risks of cardiovascular and bleeding events—indication restricted to second-line treatment and contraindicated with some cardiovascular conditions and medicines
Cilostazol (Pletal) is restricted to second-line use in patients for whom life-style modifications and other appropriate interventions have failed to sufficiently improve their symptoms. .
Hot topics
-
Recent drug-name confusion: please be vigilant as life-threatening errors may occur
We would like to remind healthcare professionals to remain vigilant with regard to drug names because serious errors have occurred when medicines with similar names have been confused
Stop Press
-
Strontium ranelate (Protelos): risk of serious cardiac disorders—restricted indications, new contraindications, and warnings
A review of available safety data for strontium ranelate (Protelos) has raised concern about its cardiovascular safety beyond the already recognised risk of venous thromboembolism. An analysis of randomised controlled trial data has identified an increased risk of serious cardiac disorders, including myocardial infarction
-
Looking for previous DSU publications?
Search by publication date above or view earlier publications in PDF
Report a safety problem
Visit our Yellow Card area to report a side effect with a medicine.
Page last modified:
29 April 2013
Head office: 151 Buckingham Palace Road, Victoria, London, SW1W 9SZ
General enquiries: info@mhra.gsi.gov.uk
To contact us about this website, use our feedback form
